Neurocrine Biosciences Inc. (NASDAQ:NBIX) went down by -3.71% from its latest closing price compared to the recent 1-year high of $136.26. The company’s stock price has collected 10.98% of gains in the last five trading sessions. Press Release reported on 01/08/21 that Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
Is It Worth Investing in Neurocrine Biosciences Inc. (NASDAQ :NBIX) Right Now?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) scored a price-to-earnings ratio above its average ratio, recording 116.54 x from its present earnings ratio. Plus, the 36-month beta value for NBIX is at 0.89. Opinions of the stock are interesting as 15 analysts out of 25 who provided ratings for Neurocrine Biosciences Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $123.17, which is $15.61 above the current price. NBIX currently public float of 90.70M and currently shorts hold a 4.75% ratio of that float. Today, the average trading volume of NBIX was 926.84K shares.
NBIX’s Market Performance
NBIX stocks went up by 10.98% for the week, with a monthly jump of 19.89% and a quarterly performance of 6.72%, while its annual performance rate touched 0.29%. The volatility ratio for the week stands at 5.92% while the volatility levels for the past 30 days are set at 3.84% for Neurocrine Biosciences Inc.. The simple moving average for the period of the last 20 days is 8.56% for NBIX stocks with a simple moving average of 0.83% for the last 200 days.
Analysts’ Opinion of NBIX
JP Morgan, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $136. The rating they have provided for NBIX stocks is “Neutral” according to the report published on August 04th, 2020.
Goldman gave a rating of “Neutral” to NBIX, setting the target price at $135 in the report published on June 29th of the previous year.
NBIX Trading at 12.27% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.63% of loss for the given period.
Volatility was left at 3.84%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares surge +15.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.61% upper at present.
During the last 5 trading sessions, NBIX rose by +10.98%, which changed the moving average for the period of 200-days by +18.08% in comparison to the 20-day moving average, which settled at $100.36. In addition, Neurocrine Biosciences Inc. saw 12.83% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NBIX starting from ROBERTS EIRY, who sale 2,632 shares at the price of $111.06 back on Jan 08. After this action, ROBERTS EIRY now owns 15,845 shares of Neurocrine Biosciences Inc., valued at $292,297 using the latest closing price.
GORMAN KEVIN CHARLES, the Chief Executive Officer of Neurocrine Biosciences Inc., sale 308,250 shares at $110.22 during a trade that took place back on Jan 08, which means that GORMAN KEVIN CHARLES is holding 441,071 shares at $33,973,877 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- +28.75 for the present operating margin
- +98.11 for the gross margin
The net margin for Neurocrine Biosciences Inc. stands at +4.70. The total capital return value is set at 22.54, while invested capital returns managed to touch 4.65. Equity return is now at value 12.60, with 6.60 for asset returns.
Based on Neurocrine Biosciences Inc. (NBIX), the company’s capital structure generated 79.11 points at debt to equity in total, while total debt to capital is 44.17. Total debt to assets is 38.58, with long-term debt to equity ratio resting at 13.62. Finally, the long-term debt to capital ratio is 7.61.
When we switch over and look at the enterprise to sales, we see a ratio of 12.85, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 8.62 and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.